A double-blind randomized placebo-controlled trial of sibutramine.
Sibutramine is a beta-phenethylamine which blocks reuptake of norepinephrine and serotonin. In this clinical study, a group of 173 patients were randomized to treatment with sibutramine at doses of 1, 5, 10, 15, 20 or 30 mg/d and were compared with placebo in a 24-week double-blind trial. There was a dose-dependent reduction in body weight, with doses of 10, 15, 20 and 30 mg being significantly greater than placebo. Weight loss was still continuing in the highest three doses at the end of the study. When drugs were discontinued patients regained weight, as expected. Side effects were generally mild and were most evident in the group treated with the highest dose. These studies suggest that sibutramine may be a valuable new drug for treatment of obesity.
Bray
G A
GA
Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
Ryan
D H
DH
Gordon
D
D
Heidingsfelder
S
S
Cerise
F
F
Wilson
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004038:Diet, Reducing; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000493:pharmacokinetics; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D010627:Phenethylamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012701:Serotonin / Q000493:pharmacokinetics
D000928:Antidepressive Agents; D003503:Cyclobutanes; D010627:Phenethylamines; D012701:Serotonin; C058254:sibutramine; D009638:Norepinephrine